華海藥業(600521.SH)半年度淨利預降5%-14%
格隆匯7月23日丨華海藥業(600521.SH)披露半年度業績預減公吿,經財務部門初步測算,公司2021年半年度實現歸屬於上市公司股東的淨利潤預計在50,000萬元至55,000萬元之間,與上年同期(法定披露數據)相比下降約5%到14%。
另外,公司2021年半年度實現歸屬於上市公司股東的扣除非經常性損益的淨利潤預計在16,000萬元至24,000萬元之間,與上年同期(法定披露數據)相比下降約55%到70%。
本期業績變化的主要原因:
1、報吿期內,公司實現歸屬於上市公司股東的扣除非經常性損益的淨利潤同比大幅下降,主要系原料藥產品價格普遍下跌及美元匯率下降進一步影響產品價格、產品銷售結構變動、環保費用持續增加等影響原料藥產品利潤大幅減少;美國製劑業務持續受FDA禁令影響以及公司生物藥、新藥研發投入不斷加大等影響所致。
2、報吿期內,公司非經營性損益預計在31,000萬元至34,000萬元之間,主要系公司出售了參股公司杭州多禧生物科技有限公司3.8597%股權的處置收益及以公允價值計量且其變動計入當期損益的金融資產本期確認的公允價值變動收益等影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.